Aura Biosciences Inc. (AURA)
NASDAQ: AURA
· Real-Time Price · USD
6.16
0.28 (4.76%)
At close: Sep 26, 2025, 3:59 PM
6.20
0.65%
After-hours: Sep 26, 2025, 07:38 PM EDT
4.76% (1D)
| Bid | 5.7 |
| Market Cap | 382.66M |
| Revenue (ttm) | 1.24M |
| Net Income (ttm) | -101.38M |
| EPS (ttm) | -1.95 |
| PE Ratio (ttm) | -3.16 |
| Forward PE | -3.05 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 6.2 |
| Volume | 303,301 |
| Avg. Volume (20D) | 210,103 |
| Open | 5.90 |
| Previous Close | 5.88 |
| Day's Range | 5.81 - 6.17 |
| 52-Week Range | 4.34 - 12.38 |
| Beta | 0.45 |
| Ex-Dividend Date | n/a |
About AURA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol AURA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for AURA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts11 months ago
+14.09%
Aura Biosciences shares are trading higher after H...
Unlock content with
Pro Subscription
11 months ago
+0.39%
Aura Biosciences shares are trading higher after the company announced multiple complete clinical responses following its single low-dose administration of Bel-sar in patients with non-muscle-invasive bladder cancer in its ongoing Phase 1 trial.
